Detection of BK virus in urine may be indicative of early infection in immunocompromised transplant patients
Early detection is critical as complications due to infection after transplantation are one of the main causes of post-operative morbidity and mortality1
Healthcare professionals and their patients now have a choice between stabilised urine and plasma samples to better manage transplant infections caused by BK virus
BKV can cause severe complications in immunocompromised transplant patients. Higher BKV DNA levels can often be present in urine prior to plasma, serving as an early predictor of an impending infection. A urine sample stabilised in cobas® PCR Media allows the integrity of urine results to be maintained, making storage and transportation simpler without the need for sample refrigeration.
Transplant patients face a number of significant challenges, including complications that can arise from viruses like BKV,
said Ann Costello, Head Roche Diagnostic Solutions.
With the FDA clearance of this non-invasive and easily collectable sample type, we now offer choices for clinicians using a standardised, automated solution to routinely monitor and manage infection risks. Together with our viral load tests for Cytomegalovirus and Epstein-Barr virus, we are committed to bringing better care to transplant patients.
The cobas BKV Test runs on the widely available, high-throughput cobas 6800/8800 Systems. It is also approved for use in CE markets with EDTA plasma and urine stabilised in cobas PCR Media as sample types.